Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563614 | 0.92 | ADORA2A (0.86) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5559861 | 0.91 | ADORA2A (0.84) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5565276 | 0.91 | ADORA2A (0.81) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5558801 | 0.91 | ADORA2A (0.75) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5564221 | 0.91 | ADORA2A (0.75) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5563496 | 0.91 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5559749 | 0.90 | ADORA2A (0.82) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5564276 | 0.90 | ADORA2A (0.81) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5563938 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1ADORA3ADORA2BMEN1 | |
| SCHEMBL5560317 | 0.88 | ADORA2A (0.79) | ADORA2AADORA1ADORA3ADORA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273865-B2 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1670805-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | claimed |
| WO-2005028484-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | claimed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | claimed |
| US-7273865-B2 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065151-A1 | Thiazolopyridine | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.